[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338828-105":59,"doc-detail-338828-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","modulation-of-cisplatin-sensitivity-through-trpml1-mediated-lysosomal-exocytosis-in-ovarian-cancer-cells-a-comprehensive-metabolomic-approach","Modulation of Cisplatin Sensitivity through TRPML1-Mediated Lysosomal Exocytosis in Ovarian Cancer Cells: A Comprehensive Metabolomic Approach","","TRPML1-mediated lysosomal exocytosis is investigated as a lever to influence cisplatin response in ovarian cancer. The study links TRPML1’s control of lysosomal calcium-dependent functions with chemoresistance, hypothesizing that blocking TRPML1 will disrupt lysosomal exocytosis and alter drug sensitivity. Four ovarian cancer cell models, including patient-derived cells, were examined using metabolomic profiling to map metabolite changes after TRPML1 inhibition. Resistant cells show cisplatin-triggered lysosomal exocytosis that is absent in sensitive cells, and pharmacologic TRPML1 intervention sensitizes resistant cells. Untargeted analysis identifies 1446 differential metabolites, with 84 significant candidates implicated across multiple pathways.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/modulation-of-cisplatin-sensitivity-through-trpml1-mediated-lysosomal-exocytosis-in-ovarian-cancer-cells-a-comprehensive-metabolomic-approach/338828/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/modulation-of-cisplatin-sensitivity-through-trpml1-mediated-lysosomal-exocytosis-in-ovarian-cancer-cells-a-comprehensive-metabolomic-approach/338828.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main biological mechanism linking TRPML1 and cisplatin sensitivity?","Question",{"text":112,"@type":113},"TRPML1 regulates lysosomal calcium-dependent processes that coordinate lysosomal biogenesis and exocytosis. By inhibiting TRPML1-mediated lysosomal exocytosis, cisplatin sensitivity is increased in resistant ovarian cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do resistant and sensitive ovarian cancer cells respond to cisplatin regarding lysosomal exocytosis?",{"text":117,"@type":113},"Lysosomal exocytosis in response to cisplatin is observed in resistant cancer cells but is absent in sensitive cancer cells.",{"name":119,"@type":110,"acceptedAnswer":120},"How were metabolomic changes identified after TRPML1 inhibition?",{"text":121,"@type":113},"An untargeted metabolomic analysis was performed on cisplatin-resistant ovarian cancer cells with TRPML1 inhibition, yielding 1446 differentially identified metabolites, with 84 significant metabolites selected for focused pathway analysis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338828,1790377173,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","cells  \nArticle  \nModulation of Cisplatin Sensitivity through TRPML1-Mediated Lysosomal Exocytosis in Ovarian Cancer Cells: A Comprehensive Metabolomic Approach  \nBoyun Kim 1, Gaeun Kim 1, Heeyeon Kim 2,3, Yong Sang Song 2,3,4 and Jewon Jung 1, *  \nCitation: Kim, B.; Kim, G.; Kim, H.; Song, Y.S.; Jung, J. Modulation of Cisplatin Sensitivity through TRPML1-Mediated Lysosomal Exocytosis in Ovarian Cancer Cells: A Comprehensive Metabolomic Approach. Cells 2024, 13, 115 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cells13020115  \nAcademic Editors: Paula Guedes De Pinho and Arun Dharmarajan  \nReceived: 29 November 2023  \nRevised: 2 January 2024  \nAccepted: 3 January 2024  \nPublished: 8 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of SmartBio, College of Life and Health Science, Kyungsung University, Busan 48434, Republic of Korea; [boyunism@gmail.com](boyunism@gmail.com) (B.K.); [kge1406@gmail.com](kge1406@gmail.com) (G.K.)  \n2 WCU Biomodulation, Department of Agricultural Biotechnology, Seoul National University, Seoul 08826, Republic of Korea; [heekim312@snu.ac.kr](heekim312@snu.ac.kr) (H.K.); [yssong@snu.ac.kr](yssong@snu.ac.kr) (Y.S.S.)  \n3 Cancer Research Institute, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea  \n4 Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea  \n* [Correspondence: jewonjung@ks.ac.kr](Correspondence: jewonjung@ks.ac.kr); Tel.: +82-51-663-5693  \nAbstract: Background: The lysosome has emerged as a promising target for overcoming chemoresistance, owing to its role in facilitating the lysosomal sequestration of drugs. The lysosomal calcium channel TRPML1 not only influences lysosomal biogenesis but also coordinates both endocytosis and exocytosis. This study explored the modulation of cisplatin sensitivity by regulating TRPML1-mediated lysosomal exocytosis and identified the metabolomic profile altered by TRPML1 inhibition. Methods: We used four types of ovarian cancer cells: two cancer cell lines (OVCAR8 and TOV21G) and two patient-derived ovarian cancer cells. Metabolomic analyses were conducted to identify altered metabolites by TRPML1 inhibition. Results: Lysosomal exocytosis in response to cisplatin was observed in resistant cancer cells, whereas the phenomenon was absent in sensitive cancer cells. Through the pharmacological intervention of TRPML1, lysosomal exocytosis was interrupted, leading to the sensitization of resistant cancer cells to cisplatin treatment. To assess the impact of lysosomal exocytosis on chemoresistance, we conducted an untargeted metabolomic analysis on cisplatin-resistant ovarian cancer cells with TRPML1 inhibition. Among the 1446 differentially identified metabolites, we focused on 84 significant metabolites. Metabolite set analysis revealed their involvement in diverse pathways. Conclusions: These findings collectively have the potential to enhance our understanding of the interplay between lysosomal exocytosis and chemoresistance, providing valuable insights for the development of innovative therapeutic strategies.  \nKeywords: TRPML1; lysosome; exocytosis; chemoresistance; metabolomics; cisplatin; arginine; ovarian cancer  \n1. Introduction  \nOvarian cancer, with its high lethality among gynecological cancers, globally ranked asthe third most common in 2020, constituting 5% of female cancer-related deaths [1] . Ovarian cancer is frequently diagnosed at an advanced stage, resulting in a 5-year survival rate of only 17% for patients [2,3] . This attributes to challenges in early detection and development o","cbCairCRrNjJVjG9","https://ap.wps.com/l/cbCairCRrNjJVjG9","pdf",3647839,17,"English","# Introduction\n## Ovarian cancer challenge and chemoresistance\n# Results\n## Cisplatin triggers lysosomal exocytosis in resistant cells\n## TRPML1 inhibition interrupts lysosomal exocytosis and sensitizes resistant cells\n# Methods\n## Cell models and metabolomic analyses\n# Discussion\n## Pathway involvement and therapeutic implications","[{\"question\":\"What is the main biological mechanism linking TRPML1 and cisplatin sensitivity?\",\"answer\":\"TRPML1 regulates lysosomal calcium-dependent processes that coordinate lysosomal biogenesis and exocytosis. By inhibiting TRPML1-mediated lysosomal exocytosis, cisplatin sensitivity is increased in resistant ovarian cancer cells.\"},{\"question\":\"How do resistant and sensitive ovarian cancer cells respond to cisplatin regarding lysosomal exocytosis?\",\"answer\":\"Lysosomal exocytosis in response to cisplatin is observed in resistant cancer cells but is absent in sensitive cancer cells.\"},{\"question\":\"How were metabolomic changes identified after TRPML1 inhibition?\",\"answer\":\"An untargeted metabolomic analysis was performed on cisplatin-resistant ovarian cancer cells with TRPML1 inhibition, yielding 1446 differentially identified metabolites, with 84 significant metabolites selected for focused pathway analysis.\"}]","Modulation of Cisplatin Sensitivity through TRPML1-Mediated Lysosomal Exocytosis in Ovarian Cancer Cells: A Comprehensive Metabolomic Approach | PDF",1790026016,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57863d291bc74d244ad05a5db6b24882.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1da741ba031e4f72bb908c56a8f1cef8.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/881718feef6ffcd80f1824693d583393.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e332a16a615966c90f143cfbc27b8405.webp",980,1385]